Oncology Researcher Forecasts Increased Use of Predictive Medicine at National Comprehensive Cancer Network Conference

HOLLYWOOD, Fla.--(BUSINESS WIRE)--The 21st century will be a time of personalized care for patients with breast cancer where tools such as biomarkers, multi-gene assays and single-gene assays will help clinicians individualize treatment, according to Peter Ravdin, M.D., Ph.D presenting at the NCCN 13th Annual Conference. However, he cautioned, further validation is still necessary to confirm some of the predictive capacities of these tests.

Back to news